Follistatin

Campbell specifically calls out both oral anabolics and harsh injectable anabolics as compounds users should reconsider in light of Follistatin's availability. He frames this as a cost-benefit analysis where Follistatin offers comparable or superior body composition outcomes without the associated systemic risks. No head-to-head comparative trial data is cited; the recommendation is based on the speaker's clinical perspective and personal opinion.

Campbell references upcoming improvements to Follistatin and similar compounds through new delivery systems and half-life extenders referred to as 'linkers.' These modifications are expected to improve the pharmacokinetic profile of the compound, making it more effective and practical for users. No specific linker chemistry or delivery mechanism is named or described in detail.

Jay Campbell argues that Follistatin represents a paradigm shift that could replace traditional anabolic steroids within 3–4 months of mainstream market penetration. Unlike anabolics, Follistatin is claimed to produce muscle-building effects without imposing a load on biological and organ system function. The speaker believes users in their 30s, 40s, and 50s who have experienced cumulative organ stress from anabolics should seriously consider switching to Follistatin.

IGF-1 naturally downregulates myostatin and increases follistatin (the myostatin antagonist), which reduces genetic limits on muscle growth. However, Dr. Bachmeyer explicitly states he thinks taking exogenous follistatin is a 'terrible idea.' The natural follistatin increase from IGF-1 signaling is an effect, not something to replicate with direct supplementation.

A safety concern raised in the community is that Follistatin may cause cardiac enlargement (cardiomegaly), which Campbell acknowledges is a circulating worry. He attributes this fear to confusion with other myostatin-inhibiting compounds rather than Follistatin specifically. Campbell dismisses the concern without citing mechanistic data or clinical evidence, representing an unsubstantiated safety reassurance.

Campbell makes a broad claim that Follistatin has no side effects, directly contrasting it with anabolic steroids. He acknowledges a common concern — that Follistatin may enlarge the heart — but dismisses this by suggesting people are confusing it with other myostatin-related compounds. No clinical data or study citations are provided to substantiate the no-side-effect claim.